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Various data sharing platforms are being developed to enhance the 
sharing of cohort data by addressing the fragmented state of data 
storage and access systems. However, policy challenges in several 
domains remain unresolved. The euCanSHare workshop was 
organized to identify and discuss these challenges and to set the 
future research agenda. Concerns over the multiplicity and long-term 
sustainability of platforms, lack of resources, access of commercial 
parties to medical data, credit and recognition mechanisms in 
academia and the organization of data access committees are 
outlined. Within these areas, solutions need to be devised to ensure 
an optimal functioning of platforms.
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          Amendments from Version 1
We thank the reviewers for their constructive comments on 
the manuscript. In view of these comments, we have added a 
section before the conclusion that clarifies our position on the 
relation between research projects and deliberative processes 
in identifying and tackling ethical implications in technology 
development. As pointed out by one reviewer, research projects 
may not be the most suitable way to tackle these issues. Within 
RRI literature, multi-stakeholder deliberation and reflexivity have 
been suggested to be either complementary to research or 
replacing research. One of the difficulties in tackling these policy 
problems with their inherent moral complexities (e.g., value 
trade-offs) lies with their anticipatory nature. If we cannot acquire 
empirical data on the consequences of building technologies, 
such as inequalities created, how can research then provide solu-
tions? And considering that these value trade-offs are inherent 
to the organisational and technical choices within platform and 
policy development, how may bioethicists (easily) study them? In 
addition to answering these questions, we have provided specific 
responses to the comments of the reviewers that were not 





Public funds are being spent on infrastructures that can help the 
sharing of medical data. However, to make these infrastructures 
work optimally, we need to overcome barriers to data sharing. 
In addition, we need to make sure that platforms themselves 
function well. This means that we need to think about potential 
overlap between platforms. We also need to make sure that 
platforms have enough public funds to keep running. Fur-
thermore, the researchers that have medical data should have 
sufficient funds to prepare the data before it is contributed to 
platforms. We also need to make sure that researchers that 
share medical data are recognized and rewarded. Lastly, we 
need to organize committees that decide on data access so 
that doubled work is limited where possible. If all these fac-
tors are addressed, we can make sure that infrastructures are 
sustainable in the long-term and that they can best serve science. 
Introduction
The integrated analysis of detailed social, environmental and 
lifestyle factors, and genetic determinants is critical to a better 
understanding of diseases, especially the risk and pathophysi-
ology of complex conditions, with the goal of benefitting the 
patient or the general population1. To achieve this, extensive 
efforts are undertaken to harmonize heterogeneous datasets for 
cross-study comparisons and informative meta-analysis, in 
particular in the field of population health studies2–4. Despite 
the obvious advantages of such harmonized and integrated 
datasets, multiple barriers exist that can stymie these efforts. 
Poor data quality, fear of misinterpretation of data and the result-
ing reputational harm, a lack of resources to prepare data for 
sharing, as well as ethical and legal restrictions, and a lack 
of incentives have been reported as reasons for not sharing 
data5–7. Medical data also remain fragmented across numerous 
medical institutions and sometimes even within the same 
institution across units, including research hospitals and uni-
versities, each featuring their own data access conditions, privi-
leges, and procedures. Although these local systems may be 
designed to efficiently request and provide access to data, they 
are generally not aimed at facilitating external data integra-
tion and reuse. This is especially the case when their primary 
aim is clinical care and research is understood as secondary in 
contrast to being complementary. The plenitude of different 
data management systems and data models, data standards and 
phenotype definitions therefore complicates the interinstitu-
tional exchange of data and the data’s integration for individ-
ual research projects. From this perspective, medical data most 
often cannot be considered as FAIR (findable, accessible, inter-
operable and reusable)8. The accessibility criterion is generally 
understood to mean “accessible under well-defined condi-
tions”, as restrictions to access for sensitive medical data occur 
under the General Data Protection Regulation (GDPR)8–11. 
As academic research is mostly funded with taxpayer money, 
the lack of FAIR data diminishes the return on investment for 
the public. This is also accompanied by an economic loss, 
with one report by PricewaterhouseCoopers, LLP (PwC) EU 
Services estimating that the quantifiable, measurable cost of 
not having FAIR research data is 10.2 billion euros per year12. 
To address this situation, the European Commission is funding 
the development of various data sharing platforms (hereaf-
ter “platforms”) for cohort data. These platforms generally 
aim to: (a) develop data catalogues to increase the visibility of 
research studies and provide an overview of shared and harmo-
nized variables across cohorts; (b) introduce data access proce-
dures in which consent criteria are represented by standardized 
Data Use Ontology (DUO) codes and data requests are 
matched to these codes semi-automatically; (c) allow the stor-
age of cohort data in local or specialized repositories, which 
are mapped into a single federated network; and (d) provide 
cloud-based virtual research environments that enable federated 
analyses of data residing in local repositories.
Although efforts to establish such platforms across Europe 
and Canada are ongoing, these initiatives may face various 
organizational and governance challenges. Salient questions 
emerge in multiple policy domains that require appropriate 
answers if platforms are to operate optimally. One such data 
sharing platform focusing on cardiovascular and imaging data is 
being built by the euCanSHare consortium (an EU-Canada 
joint infrastructure for next-generation multi-Study Heart 
research). As part of the project, the “euCanSHare Workshop on 
Incentives for Data Sharing” was set up to discuss policy chal-
lenges for platforms. The workshop convened on the 29 and 30th 
of September 2020 in an online session which brought together 
members of euCanSHare with other experts from various 
disciplines, such as medical professionals, cardiovascular 
researchers, bioethics and social science experts, and data tech-
nologists. The primary objective was to discuss the barriers, 
challenges and opportunities for data sharing in cardiovascu-
lar research as data sharing platforms become more established. 
During the meeting, experts shared their perspectives, experi-
ences and knowledge of pre-identified key topics, and were 
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able to raise additional issues they considered important. 
This article outlines the discussions of workshop participants 
on various policy areas, framed within the relevant scientific lit-
erature and policy documents. The results of this paper are 
intended to encourage researchers and policymakers to reflect 
on the policy challenges ahead and to enable the development of 
research agendas that investigate these areas and consider pos-
sible solutions. In particular, these challenges are crucial in 
the European research area, which is characterized by sub-
stantial policy divergence across institutes and countries, and 
limited direct funder intervention. Timely questions on the 
individual policy topics are outlined in Figure 1. The discussion 
addressed a range of subjects which were classified as follows: 
(1) multiplicity of platforms; (2) long-term sustainability of 
platforms; (3) lack of dedicated resources for data sharing; (4) 
access of commercial parties to medical data within platforms; 
(5) credit and recognition mechanisms in academia; and (6) the 
organization of data access committees within platforms.
Figure 1. Key questions on each policy theme.
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(1) Multiplicity of platforms
A plethora of platforms are currently being developed in par-
allel. Several consortia are undertaking distinctive projects 
within different research areas. Nevertheless, within some 
research domains multiple platforms are being set up. For exam-
ple, as part of the Innovative Medicines Initiative (IMI), the 
platform under development by the BigData@Heart project 
and the European Health Data Evidence Network (EHDEN), 
could have overlapping functions with the euCanSHare plat-
form. Therefore, the multiplicity of platforms was raised as a 
concern amongst workshop participants, specifically regard-
ing platform competition, overlap, sustainability and potentially 
redundancy. Data sharing platforms may compete on separate 
levels – data deposition, data analysis and funding application 
– with each level subject to its own competitional dynamics. 
We outline these three levels in the following paragraphs.
Data deposition. Platforms may compete to convince medi-
cal researchers to submit their cohort data. In order to allow for 
data interoperability in meta-analyses, the deposition of data 
on platforms require a certain degree of harmonization of vari-
ables, usually relying on a Common Data Model13,14. Conse-
quently, the existence of multiple platforms within one research 
area might force data generators to choose between platforms, 
which is particularly relevant when data standards diverge. 
Multiple platforms within the same research domain adopting 
diverging standards could influence future data collection. For 
prospective harmonization, platforms themselves allow flexibility 
in designing research protocols, as the need for interoper-
ability of data must not jeopardize the answering of principal 
research questions. Researchers are generally willing to har-
monize data if possible, which is more complicated if standards 
between platforms diverge. However, the acceptance of dif-
ferent standards amongst platforms diminishes the chances of 
valuable information being left out partially or completely 
if harmonization with a data standard is not possible with-
out significant data loss. One potential solution to combat the 
fragmentation of data over platforms would be to make data 
catalogues interoperable and allow them to provide information 
on data within other platforms. 
Data analysis. Presently, various platforms aim to implement 
federated methods for analyses (e.g. through DataSHIELD, 
an infrastructure and series of R packages that enables the 
remote and non-disclosive analysis of sensitive research data) of 
datasets that cannot be transferred out of the institute15. Feder-
ated methods adhere to the “code-to-data” principle instead of 
bringing data together centrally for analysis. In this way, these 
methods can help overcome legal restrictions and decrease patient 
concerns over data sharing, as data are not transferred else-
where. Competition between platforms increases when they are 
located within the same research domain and offer overlapping 
services in terms of data quality or analysis tools.
Funding application. Maintaining and improving platforms 
requires public funding or revenue streams. If the lifespan of 
a platform depends on public funding, then competition over 
project-based or structural funds might occur (see below).
Workshop participants argued that, despite potential competi-
tion, greater coordination and collaboration between platforms 
could be advantageous. The exchange of knowledge and exper-
tise between platform hosts could facilitate addressing common 
problems and avoid unnecessary duplication of effort. Some 
initiatives already exist that encourage the exchange of ideas 
and solutions, such as the joint working groups of the EU-
funded EUCAN program (of which euCanSHare is a member 
together with five other projects). Some participants proposed 
that the European Commission could take further action to 
enhance coordination between platforms, for example through 
coordination and support actions (CSA). The main objective 
of enhanced coordination should be to avoid creating a “jun-
gle” of disconnected platforms that do not share expertise, 
compete directly with one another, and make it difficult for 
researchers to see the options available for data deposition and 
analysis.
Thus, the principal questions are (a) how competition and col-
laboration between platforms should ideally be managed; 
(b) how and when exchange of expertise should occur; and 
(c) which entities should take up coordinative action.
(2) Long-term sustainability of data sharing platforms
In the past, maintenance of existing infrastructure was largely 
based on the repeated acquisition of project funding (usually 
4–5 years), which is only suitable for time-limited projects with 
specific objectives16,17. In contrast, the development of data shar-
ing platforms does not truly fit the criteria for project-based 
funding. First, platforms affect the ease of data sharing and 
the conduct of research overall. They contribute to and are 
used by a multitude of different research projects. Therefore, 
projects aimed at establishing platforms cannot be evaluated 
solely on the basis of traditional performance objectives (e.g. 
output of articles)17. Second, the valorization of platforms is 
conditional upon their long-term maintenance after initial devel-
opment. As they only start adding value to research after the 
infrastructure has been fully developed, these projects can-
not be expected to achieve their scientific objectives within 
the time limit of the initial project (i.e. the set-up phase). Some 
participants argued that in the past, the constant pursuit of entirely 
novel projects has led to an inability to sustain valuable infra-
structures. From this perspective, an excessive dependency on 
short-term funding cycles can result in wasted investments, if the 
fruits of those investments are primarily born in the long-
term. One recent review of projects using real-world data indi-
cated that few ‘data source’ initiatives have sustainability plans 
for their output, and that many cease to exist after the initial 
term of the project18. The investigators recommended that the 
“consideration of explicit mechanisms to ensure the sus-
tainability of outputs by initiatives should be a priority and 
should be a requirement for any project proposal”18. While 
scientific literature on sustainability of data sharing platforms 
is relatively scarce, several policy reports describe potential 
sustainability mechanisms for data repositories.
The Organisation for Economic Co-operation and Develop-
ment (OECD) report Business Models for Sustainable Research 
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Data Repositories discusses potential revenue streams that 
would ensure long-term sustainability for data repositories16. 
The report posits that there should be a shift from project-based 
funding to mixed-model funding. Mixed-model funding con-
sists of both structural funding and cost-recovery mechanisms 
such as data deposition fees, data usage fees, data usage 
licenses, or charges for value-added services. These mechanisms 
could be applied in several ways to acquire funds. Allocating 
additional budget to data-generating research projects to pay 
data deposition fees could be a way for funders to promote plat-
forms as the preferred providers for long-term data storage. 
Members of the Open Science unit at the Directorate-General for 
Research and Innovation have already put forward this proposal 
in general terms: “The use of trusted or certified repositories 
and infrastructures like the European Open Science Cloud 
(EOSC) will be required for research data in some Horizon 
Europe work programs”19. In terms of mixed-model fund-
ing, another report from PwC EU Services puts forward recom-
mendations along the same lines20. Data infrastructures should 
shift focus towards data monetization and value-added services 
(recommendation [REC] #23), while mixed-business models 
should be explored to strike a “healthy balance” between public 
funding and other revenue streams (REC#25)20.
Workshop participants warned that data deposition or usage 
fees could pose barriers that go against the spirit of Open 
Science. Similar arguments can be found in the literature, where 
concerns are raised that the use of fees or licenses for data usage 
could exacerbate existing inequalities between well-funded 
and less well-funded research groups, as the latter could be 
excluded from using platforms21. Furthermore, funders might 
still end up paying for the fees themselves through various other 
routes (e.g. through funding allocated to individual research 
projects)21. With regard to mixed-model funding, workshop 
participants noted that existing European infrastructures and 
repositories (e.g. the European Genome-phenome Archive 
[EGA], the Biobanking and Biomolecular Resources Research 
Infrastructure [BBMRI], Euro-Bioimaging) could theoretically 
support platforms, as they offer analytical and computational 
services that enhance reuse of data within these repositories. 
Hence, they could be considered a complementary computational 
component to supported data deposition services. As mentioned 
earlier, a greater dependence of platforms on this form of 
structural funding could lead to competition between platforms.
Policy documents and scientific literature also propose 
public-private partnerships as another way to ensure sustainabil-
ity. Recently, the vision for the Health Research and Innovation 
Cloud (HRIC) was conceptualized as an overarching frame-
work for existing data infrastructure, which promotes innovative 
funding mechanisms that involve private investors and partners 
to consolidate the outcomes of publicly-funded projects into 
long-term operational infrastructures22. A European Commission 
CSA project (HealthyCloud) has been funded to prepare the 
design for these infrastructures, which also addresses their 
long-term sustainability. Likewise, the PwC report states that 
industry should establish partnerships or collaborations with 
data infrastructures and sponsor, fund or buy data and services 
(REC#26)20. BBMRI’s Expert Centers, associated with the 
Biobanking and Biomolecular Resources Research Infrastructure 
– European Research Infrastructure Consortium (BBMRI-
ERIC), could become one such novel public-private partnership 
model which brings together expertise from industry and 
the public for collaborative analysis in the pre-competitive 
research and development environment23. Although public-private 
collaboration could be envisioned for data sharing platforms, 
access to medical data by commercial parties is an ethically sen-
sitive issue, as elaborated upon later in this article. Furthermore, 
dependence on private partners for platform maintenance 
could lead to forms of scope creep, whereby platform design 
starts to cater to the goals of private partners rather than to the 
needs of academic researchers24,25.
Further reflection is needed on (a) how data sharing platforms 
can be made sustainable in the long-term; (b) how funding 
streams can be diversified and what consequences this would 
have for open science ideals; and (c) how to address ethical 
concerns over the access of commercial companies to medical 
data and the potential undue influence of commercial actors on 
platform design. Regardless of the specific funding model, it is 
imperative that future investments enable the expansion of infra-
structures that already provide substantial value to research, 
rather than re-creating them from scratch with the renewal 
of each funding cycle. This strategy has already been successful 
in the set-up of Pan-European research infrastructures in 
specific domains (e.g. BBMRI for biobanks, European Clinical 
Research Infrastructure Network [ECRIN] for clinical trials) 
that build on a network of nationally supported hubs or nodes. 
(3) Lack of dedicated resources for data sharing
Workshop participants voiced concerns over a lack of resources 
for data sharing. Many project-based studies might not possess 
sufficient funding to harmonize existing data resources 
before submitting them to a platform. Data harmonization 
requires local financial resources, manpower, time, and niche 
expertise, which may be an entry barrier for the deposition of 
data to platforms. It should be stressed that the process needs 
to be made affordable for smaller groups, and that inequities 
may emerge in terms of competitiveness if this problem is 
not addressed. This is particularly salient within a heterog-
enous research environment like the one in Europe, where diver-
gence in research investments and academic cultures exists 
between different countries, and not all researcher teams have 
access to the same amount of funding. For example, if platform 
usage becomes more common, research teams which are unable 
to make data available to others could lose access to funding to 
sustain their cohorts. Whereas practitioners are well-aware of 
these challenges, policy reports do not yet take into account such 
inequities that could result from moving towards shared infra-
structures for cohort data26. For example, the report by PwC 
EU Services recommends making existing data FAIR on a 
demand-driven basis in order to maximize the return on invest-
ment for funders20. As smaller teams might not possess a reli-
able system to share data, they might not be able to easily 
demonstrate actual demand for their data (e.g. based on vari-
ous long-standing collaborations). Therefore, not all research-
ers may be able to acquire resources for harmonization. This 
problem occurs primarily after platform establishment, as data 
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standards set by platforms might in the long-term influence pri-
mary data generation. This is because research teams might 
opt to produce data in compliance with existing data standards 
(i.e. prospective harmonization) to avoid the cost of complex 
retrospective harmonization at a later stage. Workshop par-
ticipants also expressed concerns that research teams from 
particular areas (e.g. scientifically less competitive countries) 
might not be able to submit data due to a lack of resources, and 
that this might have downstream ethical consequences for the 
development of artificial intelligence (AI) algorithms. A lack of 
available data regarding populations of all geographical 
regions, socio-economic statuses and ethnicities diminishes the 
generalizability and fairness of algorithms. Consequently, the 
excluded populations would benefit less from the implementation 
of these tools in health care. 
Workshop participants expressed worries over a lack of institu-
tional support for processing data sharing requests. While large 
infrastructure-like studies might have an elaborate administra-
tion to enable efficient processing of data requests, smaller, 
project-like studies might require principal investigators (PIs) 
to take on more administrative work27. This creates barriers for 
data sharing, as teams must devote resources and time to data 
sharing that could be spent on their own research activities. 
Therefore, participants argued that a common infrastructure for 
data sharing would theoretically free up resources that were 
formerly dedicated to local systems. For this reason, the pooling 
of resources from larger projects could be one possible solu-
tion to address this barrier (e.g. by aiding with data harmoniza-
tion). With regards to the governance infrastructure, Shabani 
et al. raised the argument that centralizing systems associ-
ated with individual Data Access Committees (DACs) makes 
resources available28. They argue that smaller teams are better 
off setting up centralized systems as resources do not need to 
be invested in local systems, and centralized systems alleviate 
administrative burdens that come with sharing.
Key questions related to this theme include (a) how to fairly man-
age the transition costs for harmonizing data prior to platform 
submission for research teams; and (b) how the administrative 
burden (including legal considerations) for smaller research 
teams can be lowered so as to not interfere with their own 
research work.
(4) Access to medical data by commercial parties
Data sharing platforms that contain harmonized and high- 
quality data can be of great value to commercial parties. For 
example, companies could use high-quality health data to train 
AI applications for clinical predictions, diagnostics, or allocating 
therapeutics29. Some workshop participants argued that indus-
try involvement or the creation of university spin-offs speeds up 
the translation of research results into tangible applications that 
can be put into practice. Others pointed out that the access of 
commercial companies to medical data remains an ethically 
sensitive topic.
Extensive empirical work, consisting of interview studies, focus 
groups and surveys finds that citizens generally dislike sharing 
data if it results in financial profit, showcasing only minor 
differences among patients and healthy populations. In any 
case, they want more information and control over secondary 
usage, especially if their data are entrusted to public 
organizations30–35. One recurring issue is that commercial par-
ties are suspected to rank their commercial interests higher 
than the interests of patients as individuals or society. Percep-
tions of individual harm are related to privacy concerns, fear of 
stigmatization or the use of data against individuals, such 
as by private insurers or employers31,32,35–37. Collective harm 
might also be suspected if data access is seen as unjust, for 
example if there is no direct benefit for patients to donate data 
(i.e. lack of direct reciprocity) or if data access disproportionally 
furthers the profits of commercial entities (i.e. lack of indirect 
reciprocity)25,35. Additionally, unwarranted commodification of 
patient data can result in a loss of trust in public institutions, as 
the traditional roles of hospitals or universities are no longer 
fulfilled (i.e. the public good ethos is lost)31. The public trusts 
that academic institutions, hospitals or biobanks live up to their 
expectations and uphold values that are consistent with their 
place in society. Behavior perceived to be contrary to these val-
ues can violate trust and undermine willingness to participate 
in research. Empirical work has shown that private research 
organizations, funding streams from private sources, connections 
between public researchers and pharmaceutical companies, 
public-private partnerships and the location of the data stor-
age (national vs. international) all reduce trust and willingness to 
participate in medical health research25,38. Workshop partici-
pants also argued that existing concerns about data sharing 
are affected by (mis)trust in public institutions, such as the 
general reluctance to grant governmental access to health data. 
Some studies found that trust in the broader socio-political 
system (government, universities, industry, ethics committees 
and hospitals) is associated with willingness to contribute to 
biobanks39,40. Despite the stated concerns about commercial 
access to health data, patients may accept the existing tension 
within the status of commercial companies, who develop products 
indispensable to the advancement of public health, and yet 
operate on a for-profit basis25,35,36. However, for-profit activi-
ties using public data could impact the motivation for sharing 
samples and data for research purposes25,38,41. Altruism is cur-
rently considered the primary motivation for participation, and 
an increase in for-profit activities could corrode this motivation 
if data usage is not considered to sufficiently serve the public 
interest42,43. Instead, the desire for direct mutual benefit could 
replace altruism as the main motivator for research participation43.
Various reports, based on consultations with UK citizens, 
indicate that there is a gray zone in terms of acceptable data 
sharing37,44–46. Data sharing is acceptable with publicly funded 
institutions for uses that are in the public interest. Data shar-
ing is unacceptable when organizations are private and uses are 
oriented towards the private interest. In-between these extremes, 
different levels of acceptability exist for uses which serve 
a mix of public and private benefit conducted by for-profit 
organizations in the health sector37,46. A heuristic for assess-
ing acceptability includes the following topics: (a) the degree to 
which data reuse has a provable public benefit; (b) the orientation 
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of the organization (public or private interest); (c) the level 
of anonymization of the data; and (d) rigor of safeguarding, 
access and storage protocols of data37. Members of the UK public 
would generally accept a mix of public and private benefit, if 
the company operates within the health sector, and if the data 
are aggregated or anonymized37,46. Additionally, public part-
ners should be involved in product development and a return of 
benefit should exist for the public partner (e.g. reduced prices 
of products)46. Although they may initially feel skepti-
cal about sharing data with commercial entities, a process of 
deliberation may inform and convince patients (particularly 
those that are unsure) to accept the involvement of commercial 
companies in developing data-driven services and products46. 
This process of engagement and deliberation will become 
more important as the delineation between public and 
private research(ers) is blurring. In recent decades, there has 
been greater focus on translating basic research results into 
marketable products, with various forms of collaboration (e.g. 
public-private partnerships, university spin-offs) becoming 
increasingly prevalent.
The central questions about data sharing platforms are 
(a) whether access to medical data by commercial entities 
should take place; (b) which safeguards and governance mecha-
nisms need to be installed for maintaining public trust; and 
(c) how an equitable distribution of benefits can be achieved 
when commercial companies are involved.
(5) Credit and recognition mechanisms in academia
Workshop participants held diverging opinions regarding the 
need to alter recognition and evaluation systems. Some partici-
pants were very vocal about the need to thoroughly reform the 
reward system in academia, as they considered it detrimen-
tal to open science practices. Others were more skeptical of the 
ability of such reformations to incentivize data sharing, and 
instead stressed the lack of funding as the principal barrier. 
Within open science policy documents, such as the reports of 
the mutual knowledge exchange and expert/working groups 
of the European Commission, one central idea is that the 
design of credit and evaluation systems might prevent engag-
ing in open science practices, including data sharing47–56. In the 
last decade, multiple manifestos have therefore called for sub-
stantial alterations to the academic reward system. Amongst 
these, the San Francisco Declaration on Research Assessment 
(DORA), the Leiden Manifesto for Research Metrics and The 
Metric Tide have all advocated moving away from commonly 
misused metrics, developing new so-called “responsible metrics” 
and reconsidering the relation between quantitative measures 
and qualitative assessment in research evaluation56–58.
Workshop attendees found that attributing due credit to those 
that generate and share valuable data is essential for these activi-
ties to maintain their value for researchers. Some participants 
considered the inclusion of data sharing as an authorship- 
worthy activity, favorable over the former situation where this 
was not in accordance with the guidelines of the International 
Committee of Medical Journal Editors (ICMJE). Research-
ers who use, or possibly misuse, data collected by others with 
whom they have no collaboration can be controversial these 
days, as exemplified in the editorial by Longo et al. who coined 
the term “research parasites”59. However, an extrapolation of 
the collaborator model to data-intensive medical research leads 
to hyper-authorship and drives authorship inflation60,61. Opin-
ions were divided on the adverse effects of hyper-authorship, 
with some participants expressing concerns over research 
integrity while others emphasized the necessity to credit 
those that share data. It was underlined that evaluation systems 
should not use the same criteria for academics who occupy dif-
ferent roles in the scientific pipeline. As the division of labor 
within science is constantly increasing, reward systems also 
need to integrate mechanisms to recognize specialized contribu-
tions to collaborative work. Mazumdar et al. underline the neces-
sity of developing approaches to recognize those that engage 
routinely in collaborative science – “team scientists” – rather 
than lead their own projects62. These approaches generally 
require less emphasis on author position and more focus on the 
nature of the reported contributions.
In recognition of the challenges to the authorship model, in 
1997 Rennie et al. proposed a move away from authorship and 
to embrace contributorship63. Over the years, several medical 
journals such as the Journal of the American Medical Association 
(JAMA), The New England Journal of Medicine (NEJM) and 
the British Medical Journal (BMJ) have adopted such con-
tributor statements64. In 2014, contributor statements were 
standardized through the Contributor Roles Taxonomy (CRediT), 
which has since become more popular65. In the future, CRediT 
might further evolve by weighing relative contributions, being 
tailored to fit specific disciplines, being indexed with author-
ship metadata or being integrated upstream in the research 
pipeline65–67. One study found that medical researchers pres-
ently consider that author order still signals more valuable infor-
mation for evaluation purposes, although future evolutions may 
make contributor statements more valuable68. Participants of 
the workshop were generally positive about the evolution towards 
contributorship. Nevertheless, opinions diverged on the extent 
to which this shift needs to take place. While some argued 
that it is sufficient for journals to adopt contributor statements, 
others proposed a “film credits” model of contributorship, in 
which author order is completely abandoned. On this issue, par-
ticipants judged that more reflection is necessary on (a) how 
individual contributions to collaborative science may best be 
portrayed; and (b) how these statements should be used for 
evaluation purposes.
Besides contributorship, several other initiatives exist that aim 
to attribute greater credit to the producing and sharing of data-
sets and digital objects more broadly. For example, within central 
repositories such as Zenodo and Figshare, usage and citations 
are being traced and aggregated centrally in the DataCite/ 
Crossref Event Data service in standardized ways69,70. In a 
similar fashion, the Research Resource Identifier (RRID) 
enables key resources in biomedical literature to be cited using 
their identifiers such as antibodies, model organisms or software 
projects. Reuse and citation of openly available digital objects 
could then be understood as an indication of greater value in 
research, although many different contextual factors still need 
to be considered. Another example is the Bioresource Research 
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Impact Factor (BRIF) which was developed to better recognize 
the value of datasets within biobanks71. These initiatives illus-
trate that thought is being put into conferring value upon all 
research outputs (e.g. software, models, data) rather than solely 
on research articles.
In July 2019, the European Commission’s Expert Group on Indi-
cators for Researcher’s Engagement with Open Science pub-
lished the Indicator Frameworks for Fostering Open Knowledge 
and Practices in Science and Scholarship report. The report 
proposes the development of indicator toolboxes which, among 
others, entail infrastructure (or monitoring) indicators to gauge 
the evolution of open science practices at national, international 
or subject-specific levels56. Workshop participants argued that 
data sharing platforms could, in principle, be designed to align 
with these goals by tracing usage of cohort data over all cohorts, 
which could then be centrally aggregated. The collation of 
such information via platforms could enable the development 
of detailed indicators and metrics for evaluation and analyti-
cal purposes, increase the oversight of research outcomes by 
funders, and inform science policy decisions72,73. They can also 
assist in better capturing the full social value of cohort data, 
such as usage that does not result in publication. Within 
academia more broadly, the implementation of such indicators 
and metrics for data objects are considered to foster data shar-
ing practices. The discussion amongst workshop partici-
pants on their application to data sharing platforms focused on 
three key elements deemed essential to ensure the utility and 
validity of this kind of information: traceability, standardization, 
and coordination. Central questions are therefore: (a) can 
indicators relating to data sharing activities be traced within 
platforms?; (b) can this information be traced in a meaningful 
and standardized fashion?; and (c) can the fragmentation of 
standards across platforms be avoided? Future discussions 
should aim to explore technical possibilities of collecting 
indicators on data sharing through platforms and the value of 
these indicators within scientific domains.
(6) Data access committees (DACs)
Individual-level patient data of population or disease cohorts 
constitute privacy-sensitive personal data and are subject to 
controlled-access models. DACs exist to manage these processes, 
and they may be associated with institutions, biobanks, consor-
tia or with individual study teams74–76. These DACs assess the 
legitimacy of the proposed research project and whether the 
researcher is bona fide (i.e. affiliated with a scientific insti-
tution, competency)77. DACs are composed of persons with 
scientific and ethico-legal expertise. Some health consor-
tia use a decentralized model to govern secondary access to 
health data, in which each participating cohort has its own DAC 
linked to the research team or institution. In that case, by adding 
cohorts to platforms, additional DACs are added which operate 
in parallel to each other. In contrast, other consortia may also 
employ centralized models to govern data access, in which 
one DAC linked to the consortium decides upon data access 
for requests to all studies. Some workshop participants argued 
that, depending on the degree of (de)centralization of access 
procedures, the total administrative burden and the burden for 
individual cohorts may differ.
Workshop participants raised that, if cohorts maintain fully 
decentralized data access procedures, requesting access for 
multiple datasets might cause longer waiting times. For exam-
ple, when the submitted proposals are challenged on scien-
tific grounds, modifications to proposals might require several 
rounds of recirculation to all committees involved, each of which 
has their own schedule for processing those requests. Further-
more, DACs comment on the scientific validity of the pro-
posal in uncoordinated fashion, meaning that applicants might 
receive contradictory or conflicting comments (e.g. on the pre-
ferred method of analysis), or individual DACs might simply not 
respond. Since the DACs linked to each requested dataset are 
immediately involved in the evaluation of scientific propos-
als, there is also redundancy in access evaluation and the total 
bureaucratic load increases78. The bureaucratic burden for indi-
vidual DACs could also increase, particularly when the number 
of data requests rises substantially or if many initial proposals 
for data use are not scientifically sound78. Furthermore, it is 
possible that DACs could adhere to different standards to evalu-
ate proposals28,78. One DAC might constitute a board which 
conducts an elaborate assessment by looking into the scien-
tific validity of the proposal or the skills of the applicant, while 
another has a single scientist decide upon access to datasets28. 
Some workshop participants suggested that platforms should be 
non-interventionist towards the organization of DACs, compa-
rable to the policy followed by the European Genome-phenome 
Archive (EGA). Others stressed the need for DACs to oper-
ate efficiently and considered that decentralized models create 
unnecessary redundancy. Under the latter view, several different 
solutions may be pursued.
One proposed model was to use layered models of DACs 
whereby some tasks are centrally performed (e.g. assessing the 
scientific validity of proposals) while others are left to individ-
ual institutions (e.g. assessing consent and legal requirements). 
A similar concept is employed within the Monica Risks, Genetics, 
Archiving and Monograph (MORGAM) project. Adopting 
such a model within the platform would mean that when 
entering data into the platform, research teams are given the 
option either to establish an additional DAC in parallel to the oth-
ers, or to join existing partially centralized DACs that perform 
specified tasks.
Another proposed model was instating a formal data access 
structure called METADAC (Managing Ethico-social, Techni-
cal and Administrative issues in Data Access). A METADAC 
used to manage access to multi-type data and samples of seven 
longitudinal cohort studies in the UK. Data requests are evalu-
ated using specific criteria, aimed at embodying three key prin-
ciples: independence and transparency, interdisciplinarity, and 
participant-centric decision-making. The independence of the 
evaluation procedure combats data “hugging” or hoarding by 
individuals who are internal to the study79. In a joint response, 
funders of scientific research in the UK have already endorsed 
the necessity for independent data access procedures, and 
claimed to be committed to address instances “in which usage of 
data is only permitted in collaboration with a study team”. The 
particularities of a study, such as the availability and relevance 
of data, weaknesses and limitations of study design and data, 
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can be addressed by representation of principal investigators 
within the METADAC (e.g. as observers or active participants)79.
Fully centralized DACs can ensure that the data of contribut-
ing cohorts can be used interoperably for a common purpose. 
The International Cancer Genome Consortium (ICGC) uses 
such a singular DAC composed of independent experts to 
oversee access to all of its data74. The experiences with data 
access in the ICGC indicate that the aforementioned problems 
regarding the inefficiency of processing requests and guarantee-
ing that access evaluation is independent from personal inter-
ests of data producers are generally absent80. Nevertheless, the 
use of centralized DACs requires greater standardization of 
consent elements, the governance model and oversight prac-
tices. Such standardization efforts could be resisted by par-
ticipating cohorts, who are concerned about losing control over 
data usage28.
Technical solutions exist to alleviate the bureaucratic burden of 
verifying the compatibility of access requests with consent pro-
visions. Working Groups of the Global Alliance for Genomics 
and Health (GA4GH) developed the Data Usage Ontology 
(DUO) and the Automatable Discovery and Access Matrix 
(ADA-M), which aim to turn consent information into machine-
readable codes that can be matched with incoming data access 
requests81,82. This matching can take place by using smart con-
tracts within blockchain technology for sharing medical data83. 
These technologies semi-automate the matching of consent cri-
teria and therefore could reduce the administrative burden of 
having to manually check consent for each proposal. It is also 
valuable in situations where consent documents were col-
lected in different languages, as understandable codes can be 
made visible to researchers that wish to request data. 
Salient issues on DACs include (a) the viability of different 
models within platforms and their compatibility with semi-
automating parts of the data access request system and (b) 
the degree of independence DACs require. In the future, these 
models will need to be assessed for their ability to streamline 
administrative procedures and their scalability, while addressing 
possible concerns of PIs about an asserted loss of control over 
data usage.
What is the role of research and multi-stakeholder 
deliberation in tackling these policy questions?
Investigating these policy problems with their intricate ethi-
cal complexities requires multi-disciplinary approaches of 
research. While the production and evaluation of empirical data 
is useful in creating an evidence basis, the anticipatory nature of 
the outlined policy problems does not lend itself to being eas-
ily studied using only those methods. Instead, a combination of 
empirical methods (e.g., qualitative approaches, surveys…) and 
conceptual work should enable researchers to describe in-detail 
the complexities of each policy problem that is outlined. 
Research fields that already combine conceptual, qualitative, 
and quantitative approaches include Science and Technology 
Studies (STS), science policy and scientometrics, theoretical 
and empirical bioethics, Responsible Research and Innovation 
(RRI) and philosophy of science and technology. Researchers 
may, for instance, describe the ethical or political value implica-
tions of funding models for platforms in terms of inter- or intra-
national inequalities or public-private balance through concep-
tual work. If these projects sufficiently integrate perspectives 
from related fields, such as relevant economic aspects and sci-
ence policy for funding models, then these reflections can be 
considered for decision-making by policy makers in science. In 
some cases, concerns that were previously outlined in concep-
tual work may be empirically tested. For instance, the degree 
of active participation of researchers in analyses through data 
sharing platforms may be assessed based on the CRediT tax-
onomy (e.g., for countries/regions). In this case, research itself 
can live up to the ideal of RRI in that value implications in 
technology and associated policy development are understood 
before such development takes place. If it becomes apparent 
over time that these pre-identified concerns are well-grounded 
based on an empirical assessment, then further science policy 
intervention may be warranted.  
Nevertheless, approaches of reflexivity and multi-stakeholder 
deliberation should be prioritized over research in cases where 
emerging (and unanticipated) problems require urgent solu-
tions, or if the results of research are generally incapable of pro-
viding fundamental solutions to specific policy problems. The 
latter may occur if political considerations are instrumental 
in decision-making on data sharing platforms. For instance, 
multi-stakeholder deliberation with data holders is necessary 
to acquire support for the implementation of any data govern-
ance models (e.g., around the organization of DACs or overview 
mechanisms for DAC functionality). Convincing partners to 
embrace one model will not happen by presenting them an exten-
sive description of all possible data governance models that 
exist with their up- and downsides. To get partners on the same 
line, responsiveness towards their local sensitivities and mutual 
compromise is necessary. Thus, research and deliberation may 
have distinct goals. One is aimed at knowledge production and 
the other at achieving consensus. Rather than describing reflex-
ivity and stakeholder deliberation as replacing research, it 
may therefore be more fitting to consider them complemen-
tary to each other. The heterogeneity in policy areas and ques-
tions may require various actors to engage in deliberation, such 
as funding agencies, science policy makers, platform develop-
ers, DAC members and members of the medical research com-
munity (see Figure 1). It is only through the combined use of 
both research and multi-stakeholder deliberation that policy 
problems may be addressed. 
Conclusion
This work on barriers, challenges and opportunities for data shar-
ing platforms is the result of discussions with experts within 
the “euCanSHare Workshop on Incentives for Data Sharing” 
and the reviewing of existing scientific literature and policy 
documents. The future research agenda should further inves-
tigate the topics outlined here within the context of data sharing 
platforms. Data sharing platforms face multiple challenges 
related to their multiplicity and long-term sustainability, their 
perceived and actual data security, access to data by 
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commercial parties, lack of resources to prepare data for sharing, 
sharing of academic credit and recognition, and the manage-
ment of data access. A critical reflection and a thorough dis-
cussion is necessary to create a suitable policy environment 
in which data sharing platforms can thrive. Platforms by them-
selves should not be considered a panacea that solves all prob-
lems of data sharing in health research. Rather, they are to be 
understood as technical instruments that need to be undergirded 
by sound science policy. In this way, unexpected pitfalls for 
data sharing can be mitigated. Assessing public opinion on 
public-private collaboration and the access of commercial 
partners to medical data will be essential to obtain a social 
license for greater industry involvement. Comprehensive solu-
tions to these pertinent policy questions will enable platforms 
to establish themselves as core components of a productive 
academic ecosystem. When these conditions are met, future 
investments can be directed towards building on the founda-
tions laid by others and expanding the platforms for sustainable 
scientific benefit. This mode of working can best be encap-
sulated by revisiting (in part) the words of Descartes on the 
scientific method: “The best minds would be led to contrib-
ute to further progress, each one according to their bent and 
ability (…) so that one man might begin where another left off; 
and thus, in the combined lifetimes and labors of many, much 
more progress would be made by all together than anyone 
could make by themselves.”
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issues, an overarching question is whether to use a centralized approach versus competition of 
platforms, as it has been explained in detail for example concerning data access commissions. 
 
The aim of such platforms is to make data available to others through open access (OA). 
Interestingly, this concept is not as such questioned as long as appropriate consent of patients or 
those whose data are used has been obtained. Indeed, OA of data seems to be required and 
automatically judged as “good” in current discussions. Here we see only one example of issues 
that will require further thought in the future and of many yet unresolved details.
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Our general position is that making data FAIR (Findable, Accessible, Interoperable and R
eusable) is good because it serves the public interest. The primary objective of academia is 
to produce valid knowledge that is (in medical research) responsive to the health needs of 
the population. Furthermore, the allocation of public funding to this endeavour also implies 
that funds should be spent in an efficient and responsible way to maximize the return on 
investment for society. Making data FAIR helps the production of knowledge and maximize 
the return on investment by (a) facilitating meta-analyses, reanalyses, and the exploration 
of secondary hypotheses in data; (b) enabling data-inductive methods for analysis (e.g., 
machine learning); and (c) preventing redundancy in data collection. In cases where data 
sharing could lead to the production of “false” knowledge because, for instance, the risk of 
misinterpretation exists, it is advisable that data producers are actively involved in the 
analysis. Nevertheless, one may argue that despite the risk of misinterpretation, the overall 
benefits of openly sharing (i.e., without active involvement of data partners) still outweigh 
the downsides. There are still various factors that still need to be respected for data sharing 
to be “good”. First, the persons whose data is being used must have given their informed 
consent to sharing, or sharing data should be grounded in a legitimate or public interest. 
Second, the purposes of data sharing must not conflict with the interests or values of 
individual research participants or with important societal (or communal) values. This 
means that data sharing for particular purposes may not be desirable (e.g., data sharing for 
purposes that may cause harm to communities). Thirdly, data sharing should take into 
account power differentials in between partners in data sharing. This means that, although 
the purpose of data sharing may be good, the process of data sharing is also relevant. One 
such example is data sharing between researchers in high-income countries and low-middle 
income countries. In this case, efforts to establish an equitable partnership may include 
knowledge exchange to compensate for structural inequalities. We have not further 
elaborated on the cases in which data sharing is undesirable in the article.  
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that emerged from a euCanSHare workshop. In this article, the authors articulate several areas of 
concern for which solutions are needed and distill each issue down to a set of policy/research 
questions that need to be answered.  
 
As a bioethicist, I was struck by the degree to which each of these issues and questions is morally 
charged. This is true even of apparently "technical" or "logistical" issues (e.g. platform overlap, 
funding, data access committees models). For example (as the authors note) inequities can be 
introduced by adopting particular approaches to harmonising data, particular funding models or 
models for membership of data access committees.  
 
The article does a good job of articulating the ethical dimensions of each issue. Both (brief) 
theoretical arguments and empirical studies are drawn upon to try to shed light on how some of 
these issues might be conceptualised and addressed (particularly in relation to commercial access 
and academic credit). 
  
While these high-level summaries of the ethical issues are appropriate for the purposes of this 
article, they only hint at the complexity of each issue. I, therefore, think that more thought needs 
to be given (if not in this article then as a next step) to how to manage this moral complexity. In 
particular, thought should be given to 
precisely how "[t]he future research agenda should further investigate the topics outlined 
here within the context of data sharing" and  
 
1. 
where research needs to be replaced (or at least supplemented) with ongoing reflexivity 
and multi-stakeholder deliberation about whatever data models are put into place. 
2. 
The principles of "responsible (research and) innovation" might be useful here, as these recognise 
the need for both anticipation of ethical issues and ongoing revision of whatever decisions are 
made. 
 
There are a few minor grammatical errors in the article
p5/12: "output articles" should be "output of articles" 
 
○
p7/12: "inacceptable" should be "unacceptable"○
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